Skip to main content

Table 2 Multivariate cox analysis of immune risk score and clinical variables in training dataset, validation dataset-1 and validation dataset-2

From: An individualized immune prognostic signature in lung adenocarcinoma

  Training dataset HR (95% CI) p value Validation dataset-1 HR (95% CI) p value Validation dataset-2 HR (95% CI) p value
IRS 10.71 (5.72–20.07) < 0.01 2.68 (1.15–6.27) 0.02 3.71 (1.33–10.33) 0.01
Age 1.03 (1.02–1.05) < 0.01 1.03 (1.01–1.04) < 0.01 1.00 (0.98–1.03) 0.65
Gender male 1.08 (0.81–1.44) 0.60 1.22 (0.93–1.59) 0.14 1.69 (1.14–2.51) < 0.01
Stage
 I Reference      
 II 2.12 (1.56–2.89) < 0.01 1.85 (1.28–2.69) < 0.01 2.13 (1.30–3.51) < 0.01
 III 2.52 (1.38–4.59) < 0.01 5.57 (3.66–8.48) < 0.01 3.37 (2.05–5.54) < 0.01
 IV 2.58 (0.82–8.18) 0.11 NA NA 4.02 (1.78–9.08) < 0.01
Purity 1.31 (0.48–3.53) 0.60 1.41 (0.52–3.85) 0.50 0.95 (0.23–3.91) 0.95
  1. IRS immune risk score, CI confidence interval, HR hazard ratio